Crestor, Zocor Comparison May Be More Useful Than ASTEROID – Editorial

A trial comparing high doses of AstraZeneca's Crestor and Merck's Zocor would be more informative than the open label, single-arm ASTEROID study evaluating the effects of high-intensity Crestor on regression of coronary atherosclerosis, according to an editorial in the March 13 issue of the Journal of the American Medical Association